FDA-approved agents for inflammatory diseases targeting the IL-6/JAK/STAT axis are being evaluated together with novel STAT3-specific inhibitors for the treatment of hematological malignancies and solid tumors [243]. Here, SOAT1 is linked to hematologic disorder.